ArticleJournal of thoracic disease2025
Critical role of spread through air spaces in prognosis of stage IA3 non-small cell lung cancer: insights from a real-world multicenter study.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pathological stage IA3 non-small cell lung cancer (NSCLC) has higher recurrence rates and poorer prognosis than stages IA1 and IA2. This study systematically evaluates the prognostic impact of spread through air spaces (STAS) subtypes and related histomorphological factors, providing new insights for risk stratification in stage IA3 NSCLC. Methods: We analyzed 256 pathological stage IA3 NSCLC patients from multiple thoracic centers in Fujian Province between January 2013 and June 2019. Clinical and pathological data were collected, and Chi-squared tests identified factors associated with extensive STAS. Patients were stratified using various STAS assessment methods and other pathological features to evaluate risk factors for progression-free survival (PFS) and overall survival (OS). Results: STAS was observed in 115 patients (44.9%). Extensive STAS correlated with a family history of lung cancer, solid nodules, vascular invasion, micropapillary components, tumor budding, and STAS distance >1 mm. Multivariate analysis identified smoking history, tumor-stroma ratio, histopathological type, micropapillary components, and the STAS cell nest subtype as independent risk factors for PFS. Patients were categorized into low- (0 factors; 3.06%), medium- (1-2 factors; 9.66%), and high-risk groups (≥3 factors; 76.92%). For OS, significant risk factors included smoking history, tumor-stroma ratio, carcinoembryonic antigen (CEA) levels, and STAS cell nest subtype. Conclusions: The cell nest STAS subtype, tumor-stroma ratio, and smoking history are independent prognostic factors influencing PFS and OS in stage IA3 NSCLC. These findings underscore the need for detailed assessments of STAS subtypes and histopathological heterogeneity to refine prognostic evaluations and optimize clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.